Stocks and Investing
Stocks and Investing
Tue, October 5, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, October 4, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mani Foroohar Maintained (BBIO) at Buy with Increased Target to $68 on, Oct 4th, 2021
Mani Foroohar of SVB Leerink, Maintained "BridgeBio Pharma, Inc." (BBIO) at Buy with Increased Target from $66 to $68 on, Oct 4th, 2021.
Mani has made no other calls on BBIO in the last 4 months.
There is 1 other peer that has a rating on BBIO. Out of the 1 peers that are also analyzing BBIO, 0 agree with Mani's Rating of Hold.
This is the rating of the analyst that currently disagrees with Mani
- Geoff Meacham of "B of A Securities" Upgraded from Hold to Strong Buy and Held Target at $75 on, Friday, September 10th, 2021
Contributing Sources